Table 2.
Characteristics of study participants.
| Food panel | Inhalant panel | |
|---|---|---|
| Total number | 53 | 104 |
| Demographic characteristics | ||
| Number of male (%) | 21 (39.6) | 56 (53.8) |
| Age, median [1Q, 3Q] | 32 [9,55] | 35 [20.8, 56.5] |
| Age, range | 1–85 | 5–78 |
| Number of pediatric patients (%)a | 16 (30.2) | 24 (23.1) |
| Clinical symptoms and signs | ||
| Urticaria (%) | 32 (60.4) | 3 (2.9) |
| Dermatitis (%) | 14 (26.4) | 1 (1.0) |
| Allergic rhinitis (%) | 5 (9.4) | 87 (83.7) |
| Allergic bronchitis (%) | 1 (1.9) | 4 (3.8) |
| Asthma (%) | 2 (3.8) | 5 (4.8) |
| Anaphylaxis or angioedema (%) | 6 (11.3) | 1 (1.0) |
| Others (%) | 8 (15.1)b | 4 (3.8)c |
| Matched pairs in each comparison | ||
| AlloScreen vs. Allostation Smart II | 43 | 90 |
| Allostation Smart II vs. RIDA | 30 | 79 |
| Allergy-Q vs. RIDA | 40 | 93 |
a
Pediatric patients are defined as individuals with age <20 years.
b
Others include xerotic eczema, erythema multiforme, drug eruption, and insect bite.
c
Others include adenoid vegetation, chronic sinusitis, and sleep apnea.